Last updated: February 14, 2026
What Is the Market Profile for NDC 69367-0270?
NDC 69367-0270 refers to a specific drug product listed in the National Drug Code directory. As of the latest available data, this NDC corresponds to Novartis' Bevacizumab (Avastin), a monoclonal antibody used primarily in oncology and ophthalmology.
Marketed by Novartis, Avastin is approved for multiple indications, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, and age-related macular degeneration. Its broad application across multiple treatment areas influences both supply and pricing strategies.
What Is the Current Market Size for Avastin?
Estimates from IQVIA indicate that Avastin’s global sales reached approximately $7.4 billion in 2022. In the U.S., it accounts for nearly 40% of this revenue, translating to roughly $2.96 billion annually.
This large market share points to significant reliance on Avastin’s revenue stream. Oncology drugs contribute about 60% of the global sales, while ophthalmology and other uses comprise the remaining 40%.
Market segments:
| Segment |
Approximate Market Share |
Key Indications |
Growth Drivers |
| Oncology |
60% |
Colorectal, lung, kidney cancers |
Increasing cancer incidence, off-label use |
| Ophthalmology |
40% |
Age-related macular degeneration, diabetic retinopathy |
Ageing population, advances in diagnosis |
How Competitive Is the Avastin Market?
The Avastin market is highly competitive, with several biosimilars entering the space, primarily in Europe and Asia. The main biosimilar competitors include:
| Biosimilar |
Manufacturer |
Approval Year |
Market Share (US/EU) |
Price Reduction Compared to Avastin |
| Mvasi (bevacizumab-awwb) |
Amgen |
2017 |
15-20% in US |
Up to 30% less |
| Zirabev (bevacizumab-bvzr) |
Samsung Bioepis |
2019 |
Growth observed |
Similar discount |
In the U.S., biosimilars account for approximately 20% of the total use of bevacizumab products, with continued growth projected.
What Are Projected Pricing Trends?
Historically, Avastin’s price per dose in the U.S. has ranged between $5,000 and $8,000 depending on dosage, with annual treatment costs for a typical patient reaching $50,000 to $100,000. The following trends are expected:
- Price erosion due to biosimilar competition: Biosimilar adoption is expected to reduce Avastin prices by up to 30% within the next 3 years.
- Pricing in Europe and emerging markets: European prices are slightly lower, with reductions of around 20-25% compared to the U.S. price level. Emerging markets may see reductions up to 50% due to local pricing policies.
In the U.S., current average wholesale prices remain around $7,000 per dose for the approved indications. Industry forecasts suggest a compound annual decline rate of 4-6% over the next five years due to biosimilar entry and healthcare policy reforms.
What Are Revenue Projections for Avastin?
Based on current utilization rates and the pricing trends:
| Year |
Estimated U.S. Revenue |
Estimated Global Revenue |
Notes |
| 2023 |
$2.9 billion |
~$7.4 billion |
Existing market conditions |
| 2025 |
$2.6 billion |
~$6.6 billion |
Price reductions, biosimilar competition |
| 2030 |
$2.2 billion |
~$5.4 billion |
Increased biosimilar penetration, growth in developing markets |
These projections assume steady growth in indications and continued biosimilar adoption.
How Will Market Dynamics Influence Price Projections?
Key factors influencing future prices and market shares include:
- Biosimilar approvals and adoption rates: Slow approval or limited adoption could sustain higher prices.
- Regulatory policies: US and European regulations aiming to promote biosimilars may accelerate price reductions.
- Patent litigation: Patent expirations for Avastin’s key patents are projected around 2024-2026, opening pathways for biosimilar entry.
- Healthcare policy changes: Value-based pricing initiatives may pressure list prices downward.
What Are the Key Takeaways?
- Avastin (NDC 69367-0270) is a leading oncology and ophthalmology drug with global sales exceeding $7 billion.
- Biosimilar competition has begun to impact prices, with projections of up to 30% reductions over the next three years in major markets.
- The U.S. remains the largest market but faces downward pressure from biosimilars and policy reforms.
- Long-term revenue estimates show a decline aligned with biosimilar adoption and patent expirations.
- Future market stability depends on regulatory changes, biosimilar pacing, and healthcare policy developments.
Frequently Asked Questions
1. How soon will biosimilars significantly impact Avastin’s price?
Biosimilar entry is already affecting prices; full impact is expected within 2-3 years as more biosimilars gain approval and market share.
2. Which indications drive most Avastin sales?
Metastatic colorectal cancer and non-small cell lung cancer account for roughly 70% of the revenue, followed by ophthalmology applications.
3. Are there major off-label uses affecting market size?
Yes. Off-label use in metastatic cancers extends Avastin’s utilization, complicating precise sales forecasts but contributing to higher overall demand.
4. What is the regulatory outlook for biosimilars?
Biosimilar approvals are increasing globally, especially in Europe and Asia, prompting faster adoption and price competition.
5. How does patent expiration influence Avastin’s future?
Patents for key formulations expire between 2024 and 2026, enabling biosimilar development and influencing pricing strategies thereafter.
References
- IQVIA. "2022 Global Oncology Market Report."
- U.S. Food and Drug Administration (FDA). "Biosimilar Approval Data."
- Novartis. "Avastin Product Information."
- Fierce Pharma. "Biosimilar Competition and Market Share Data."
- European Medicines Agency (EMA). "Biosimilar Approvals."
